老年人群中玻璃体黄斑界面异常与青光眼(MONTRACHET研究)
基于法国第戎2009至2013年MONTRACHET人群研究,纳入1130名75岁以上参与者(2225眼),评估青光眼患者玻璃体黄斑界面异常(VMIA)患病率;全部VMIA在青光眼与非青光眼参与者间无统计学差异(51.85% vs 53.92%,P=0.372),多变量分析后各关联不再显著。
要点
- 全部VMIA患病率在青光眼与非青光眼参与者间无统计学差异(51.85% vs 53.92%,P=0.372)。
- 单变量分析中玻璃体黄斑粘连在非青光眼参与者更常见(18.39% vs 10.78%,P=0.036)。
- 无防腐剂降眼压滴眼液治疗眼的黄斑囊肿患病率高于含防腐剂降眼压滴眼液治疗的非青光眼对照眼(26.67% vs 3.37%和5.76%,P<0.001)。
核心结论
- 该老年人群中VMIA患病率高,青光眼与非青光眼参与者相似。
- 作者认为,在老年患者青光眼管理中参考黄斑光学相干断层扫描提供的信息时应谨慎。
研究设计与样本
- 基于人群的研究(MONTRACHET研究),2009至2013年在法国第戎开展,纳入75岁以上个体。
- 共纳入1130名参与者(2225眼),平均年龄82.3±3.8岁,女性占62.74%。
主要发现
- 全部VMIA在青光眼患者与非青光眼参与者间无统计学差异(51.85% vs 53.92%,P=0.372)。
- 单变量分析中玻璃体黄斑粘连在非青光眼参与者更常见(18.39% vs 10.78%,P=0.036)。
- 视网膜前膜在青光眼人群更常见(47.06% vs 38.13%,P=0.018)。
- 黄斑囊肿患病率在两组间相当(7.84% vs 5.64%,P=0.262)。
- 使用无防腐剂降眼压滴眼液治疗眼的黄斑囊肿患病率高于使用含防腐剂降眼压滴眼液治疗的非青光眼参与者眼(26.67% vs 3.37%和5.76%,P<0.001);多变量分析后这些结果不再显著。
临床怎么用
- 作者认为,在老年患者青光眼管理中参考黄斑光学相干断层扫描提供的信息时应谨慎。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the prevalence of vitreomacular interface abnormalities (VMIAs) in a French elderly glaucomatous population. METHODS: Using a population-based study, the MONTRACHET (Maculopathy Optic Nerve nuTRition neurovAsCular and HEarT diseases) study conducted in Dijon from 2009 to 2013 in individuals older than 75 years, the prevalence of VMIAs was estimated on glaucoma patients. RESULTS: A total of 1130 participants (2225 eyes) were included in the study. The mean age of participants was 82.3 ± 3.8 years, and 62.74% were women. Regarding the frequency of all VMIAs, there was no statistical difference between glaucoma patients and nonglaucoma participants (51.85% vs. 53.92%, respectively, P = 0.372). In univariate analysis, vitreomacular adherences were more frequent in nonglaucoma participants (18.39% vs. 10.78%, P = 0.036). Epiretinal membranes were more frequent in the glaucomatous population (47.06% vs. 38.13%, P = 0.018). The prevalence of macular cysts was comparable in the two groups (7.84% vs. 5.64%, P = 0.262). Macular cysts were more frequent in eyes treated with preservative-free, IOP-lowering eye drops when compared with the eyes of nonglaucomatous participants treated with IOP-lowering eye drops containing a preservative (26.67% vs. 3.37% and 5.76%, respectively, P < 0.001). In multivariate analysis, these results were no longer significant. CONCLUSIONS: The prevalence of VMIAs was high in this elderly population and similar in both glaucomatous and nonglaucomatous participants. The information provided by macular optical coherence tomography scans should be considered with caution when used for glaucoma management in elderly patients.
引用
- Blanc J, Seydou A, Ben Ghezala I, et al. Vitreomacular Interface Abnormalities and Glaucoma in an Elderly Population (The MONTRACHET Study). Invest Ophthalmol Vis Sci. 2019. PMID: 31067319. doi:10.1167/iovs.18-26510
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。